Subscribe To

Price Alert Latest News Economic Calendar News

CYTK / Cytokinetics: Biotech That Should Be On Your Radar With Several Catalysts In 2022

Cytokinetics establishes partnership deal with Royalty Pharma for omecamtiv mecarbil and aficamten. Up to $450 million in total is expected for this particular deal. NDA Filing of omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction is expected any day now in early 2022. Read More

Demo Live Account See Partner Details

Content Topics

Invesco

Bulletshares

2023

Usd

Emerging

Markets

Debt

Etf

Bsce

Cytokinetics

Biotech

Should

Several

Catalysts

Stock

CYTK

Posted: Jan 7 2022, 19:51

Author Name: Seeking Alpha

CYTK News

By Seeking Alpha
November 3, 2023

Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript

Cytokinetics, Incorporated (NASDAQ:CYTK ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice

By Zacks Investment Research
November 2, 2023

Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.35 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of

By Reuters
October 31, 2023

Cytokinetics exploring options after receiving takeover interest - Bloomberg News

Heart diseases-focused drug developer Cytokinetics is weighing options after receiving takeover interest, Bloomberg News reported on Tuesday, citing p

By GlobeNewsWire
October 23, 2023

Cytokinetics to Announce Third Quarter Results on November 2, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to repor

By Zacks Investment Research
October 9, 2023

Cytokinetics (CYTK) Soars 11.4%: Is Further Upside Left in the Stock?

Cytokinetics (CYTK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revi

By GlobeNewsWire
September 7, 2023

Cytokinetics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is schedule

By Seeking Alpha
August 3, 2023

Cytokinetics, Incorporated (CYTK) Q2 2023 Earnings Call Transcript

Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice P

By Zacks Investment Research
August 3, 2023

Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.